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Objective: Our objectives are 2-fold: (1) to serially measure the release of endothe-
lin and graft-conduit endothelin sensitivity during and after coronary artery bypass
grafting and (2) to define potential relationships of changes in endothelin levels to
perioperative parameters.
Methods: Endothelin plasma content was measured in patients (n = 105) undergo-
ing bypass grafting from select vascular compartments before operations and at spe-
cific intervals up to 24 hours postoperatively. Endothelin sensitivity was determined
in isolated internal thoracic artery segments.
Results: Systemic arterial and pulmonary arterial endothelin  levels were increased
by approximately 50% immediately after bypass grafting and increased by another
85% during the first 24 hours postoperatively. Endothelin levels were highest in
patients with prolonged ventilatory requirements and extended stays in the intensive
care unit (10.2 ± 0.8 vs 13.2 ± 1.1 fmol/mL, P = .02, and 9.8 ± 0.7 vs 13.9 ± 1.2
fmol/mL, P = .01, respectively. Endothelin  sensitivity of the internal thoracic artery
was increased in patients requiring prolonged vasodilator support with nitroglyc-
erin.
Conclusions: Systemic and pulmonary arterial endothelin levels remained increased
for at least 24 hours postoperatively. Prolonged pharmacologic management and
increased intensive care unit stay were associated with increased systemic endothe-
lin release and heightened graft-conduit sensitivity to endothelin.
Endothelin-1 (ET-1) is a potent bioactive peptide that has beendemonstrated to influence vascular resistance properties in thesystemic, pulmonary, and coronary circulation.1,2 Moreover,exposure of myocardial preparations to ET-1 has been shown toinfluence contractile performance.3,4 Elevated plasma levels ofET-1 have been identified in a number of cardiovascular disease
states, as well as during coronary artery bypass grafting (CABG) operations
requiring cardiopulmonary bypass (CPB).5,6 Increased release of ET-1 may mod-
ulate systemic hemodynamics and myocardial contractility, which would have
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particular relevance in the post-CABG setting.7,8
However, the influences of ET-1 on parameters of patient
recovery after CABG remain unknown. Accordingly, the
first objective of the present study was to examine poten-
tial relationships between the temporal profile of systemic
arterial and pulmonary arterial ET-1 plasma levels to spe-
cific indices of recovery after CABG. The vasoconstric-
tive effects of ET-1 may have particular relevance to the
vascular grafts used as CABG conduits. Therefore, the
second objective of this study was to examine the relation
between CABG conduit ET-1 sensitivity and postopera-
tive parameters of recovery. This project tested the
hypothesis that changes in ET-1 production and sensitivi-
ty were associated with alterations in specific periopera-
tive parameters of recovery, which may contribute to a
complex postoperative course of recovery.
Materials and Methods
Patients
After approval by the Human Subjects Review Committee of the
Medical University of South Carolina, 105 consecutive patients
undergoing elective CABG operations provided informed con-
sent to participate in this study. Standard induction and mainte-
nance of anesthesia was accomplished with a combination of
sufentanil, midazolam, and isoflurane. Systemic heparinization
was achieved with a heparin dose of 400 U/kg. CPB was main-
tained at a cardiac index of 2.0 to 2.4 L · min–1 · m–2. Initial car-
dioplegic arrest was accomplished with antegrade administra-
tion of a 500-mL solution of D5 0.2 NaCl containing 29 mL of
tromethamine (THAM) buffer, 34 mL of adenosine citrate phos-
phate dextrose, and 60 mEq of KCl (120 mEq/L K+). This was
followed immediately by retrograde administration of 300 mL
of the cardioplegic solution. Approximately every 20 minutes,
cardioplegic arrest was maintained with a 400- to 700-mL retro-
grade administration of the cardioplegic solution with a lower
potassium concentration (60 mEq/L). At the termination of CPB,
heparin was neutralized with protamine at a 1:1 ratio. Discharge
criteria from the intensive care unit (ICU) included a complete
wean from all vasoactive and inotropic infusions, extubation
without pulmonary support, and no evidence of major organ sys-
tem failure.
Nitroglycerin infusion was administered postoperatively for sys-
temic or pulmonary hypertension (defined as a 20% increase over
preoperative levels) and ST segment elevation or depression of
greater than 1 mm. Epinephrine infusion was administered postoper-
atively to maintain a cardiac index of greater than 2.0 L · min–1 · m–2.
Sample Time Points
A 3-mL sample of blood was obtained from the radial artery before
the induction of anesthesia to obtain a baseline systemic arterial
ET-1 measurement. Samples were then collected from the radial
artery and pulmonary artery at the following time points: just
before CPB, at aortic crossclamp removal, immediately after sep-
aration from CPB, 1⁄2 hour after CPB, and 6 and 24 hours postop-
eratively.
ET-1 Measurement
Whole blood for ET-1 measurement was collected in 3-mL tubes
with ethylenediamine tetraacetic acid on ice. Plasma separated by
centrifuging at 6000g for 15 minutes at 4°C was transferred to
polypropylene tubes and stored at –80°C. One milliliter of plasma
was eluted over a cation exchange column (C-18 Sep-Pak; Waters
Associates, Milford, Mass) and dried by means of vacuum cen-
trifugation. The samples were reconstituted in 0.02 mol/L borate
buffer, and a high-sensitivity competitive ET-1 radioimmunoassay
was performed (RPA 545; Amersham, Arlington Heights, Ill).
Recovery from the extraction procedure was 75% ± 5% on the
basis of spiked plasma standards (4-20 fmol/mL). For repeated
measurements of plasma samples and the inclusion of plasma sam-
ples with a known concentration of exogenous ET-1 added to the
sample, the coefficient of variation was less than 12%. By using an
optimized extraction procedure, the sensitivity of this assay system
was 0.0025 fmol/mL. The within-assay precision for duplicate
determinations was determined for 20 plasma samples, and the
coefficient of variation was 4.4%. The between-assay precision
was assessed by repeated measurements of 20 plasma samples in
successive radioimmunoassay procedures, and a coefficient of
variation of 6.1% was determined.
CABG Conduit Collection and Experimental Protocol
Remnant segments of internal thoracic artery (ITA; n = 38) and
saphenous vein (n = 34) harvested for use as CABG grafts were
collected from a subset of patients. After anastomosis, remaining
grafts were placed into iced oxygenated Krebs-Henseleit buffer
(4.6 mmol/L KCl, 2.5 mmol/L CaCl2, 1.2 mmol/L KH2PO4, 118
mmol/L NaCl, 2.5 mmol/L NaHCO3, and 11 mmol/L glucose) and
immediately transported to the laboratory. Vascular rings were pre-
pared for tension measurements, as described by this laboratory
previously.9 Developed tension from each ring was measured by
using digital force transducers (Radnoti, Monrovia, Calif), and the
digital signal was acquired for analysis by an acquisition system
(BioBench; National Instruments, Austin, Tex). After a 1-hour
equilibration period, each ring was exposed to increasing concen-
trations of ET-1 (0.1-100 nmol/L; Sigma, St Louis, Mo) at 20-
minute intervals. Steady-state vasoconstriction was achieved for
each ET-1 concentration, and maximum developed tension was
recorded. Developed tension for each vessel was reported as a per-
centage of maximal KCl-induced (80 mmol/L) vasoconstriction to
normalize for differences in mass and thickness between ring
preparations.9 The concentration-tension curves were subjected to
regression analysis by means of an exponential curve-fitting algo-
rithm to compute the ET-1 concentration necessary to induce 50%
maximal vasoconstriction (EC50). This EC50 computation was
used as an index of vessel sensitivity for ET-1. Thus, lower EC50
values reflect an enhanced sensitivity of the vessel to the vasocon-
trictive effects of ET-1.
Data Analysis
Hemodynamic parameters and plasma ET-1 levels at each time point
were first evaluated with a multi-way analysis of variance
(ANOVA). If the ANOVA revealed significant differences, pairwise
tests of individual group means were compared by Bonferroni
adjusted probabilities. Categoric analyses of postoperative outcome
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variables defined as ICU time, hospital stay, ventilator time, mean
pulmonary artery pressure, and nitroglycerin treatment were placed
into discrete intervals and analyzed with respect to ET-1 levels.
These categories were chosen before data analysis on the basis of
normal uncomplicated postoperative recovery periods for ICU time,
hospital stay, and ventilator time for patients undergoing CABG
operations in our institution (24 hours, 5 days, and 12 hours, respec-
tively). By means of these cut points, individual comparisons of ET-
1 values were performed by an unpaired t test. After the ET-1 mea-
surements, patients were grouped with respect to the presence or
absence of diabetes. Systemic arterial plasma ET-1 levels were com-
pared between the diabetic and nondiabetic groups by ANOVA and
pairwise comparisons with Bonferroni adjusted probabilities. EC50
values for both ITA and saphenous vein were compared with these
outcomes variables by means of the same approach. All statistical
procedures were performed with the BMDP statistical software
package (BMDP Statistical Software, Inc, Los Angeles, Calif).
Results are presented as means ± SEM unless indicated otherwise.
Results
Demographic and perioperative clinical descriptive data for
the patients enrolled in this study are presented in Table 1.
Changes in systemic hemodynamics after CPB were consis-
tent with past reports and are summarized in Table 2.6 Heart
rate, cardiac output, and mean arterial and pulmonary pres-
sures were significantly elevated after CPB and postopera-
tively compared with values before CPB.
Systemic arterial and pulmonary arterial ET-1 levels were
elevated by approximately 50% over baseline values through-
out the surgical procedure (Figure 1). During the first 24 hours
of the postoperative period, ET-1 levels were further increased
in both vascular compartments. Systemic and pulmonary arte-
rial ET-1 values at 6 and 24 hours postoperatively were
increased 160% over baseline values and increased 85% rela-
tive to values obtained during the surgical procedure.
In the present study, 36% of the patients were diabetic. In
the nondiabetic patients the baseline systemic arterial ET-1
values were 4.2 ± 0.3 fmol/mL (95% confidence intervals
[CI], 3.5-4.8 fmol/mL). In the diabetic patients baseline ET-
1 levels were higher than those in nondiabetic patients (5.4
± 0.7 fmol/mL; 95% CI, 3.4-6.2 fmol/mL), but this did not
reach statistical significance (P = .137). At 6 hours after
CPB, the systemic arterial ET-1 levels for the nondiabetic
Figure 1. Systemic and pulmonary arterial plasma ET-1 levels during and after CPB in patients undergoing coro-
nary revascularization. Systemic and pulmonary artery ET-1 levels were elevated during CPB compared with pre-
operative baseline values. Furthermore, ET-1 levels were further elevated at 6 and 24 hours postoperatively rela-
tive to values measured during the operative procedure. BASE, Before the operation; PRE-CPB, immediately
before CPB; CCR, aortic crossclamp removal; 0, immediately after bypass cessation; 1/2, 30 minutes after bypass
cessation; 6, 6 hours after the operation; 24, 24 hours after the operation (#P < .05 versus BASE and *P < .05 versus
PRE-CPB).
TABLE 1. Patient characteristics and clinical perioperative
data
Range
Mean ± SD Lower Upper
Age (y) 62 ± 12 33 87
No. of grafts 3 ± 1 2 6
Bypass time (min) 114 ± 30 50 185
Ventilation time (h) 12 ± 6 1 25
ICU time (h) 29 ± 19 15 108
Hospital stay (d) 5 ± 3 2 33
Data are presented as means ± SD where shown (n = 105).
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patient sample were 11.4 ± 0.9 fmol/mL (95% CI, 9.5-13.3
fmol/mL). In the diabetic patients systemic arterial ET-1
levels at 6 hours after CPB were 11.9 ± 1.1 fmol/mL (95%
CI, 9.7-14.2 fmol/mL) and were not different from nondia-
betic patients (P = .55).
Elevated ET-1 levels in the systemic arterial circulation 6
hours after the operation were observed in patients with pro-
longed ICU time, as defined by greater than 24 hours
(Figure 2). In addition, systemic arterial ET-1 levels at 6
hours postoperatively were higher in patients with pro-
longed hospital stays of more than 5 days (Figure 2).
Patients with elevated mean pulmonary artery pressures
(defined as greater than 20 mm Hg) also displayed a signif-
icant increase in pulmonary artery ET levels at 6 hours post-
operatively (Figure 3). Furthermore, prolonged ventilatory
support of more than 12 hours was associated with higher
pulmonary arterial ET-1 levels at 6 hours postoperatively
(Figure 3).
CABG conduit sensitivity to ET-1 was determined by
calculating the EC50 value from the ET-1 concentration-
response curve generated from each isolated vessel (Figure
4). The average ET-1 EC50 value for all ITA vessels exam-
ined was 10.2 ± 0.9 nmol/L. χ2 Analysis of ITA ET-1 EC50
values and nitroglycerin treatment at 24 hours postopera-
tively revealed that only 10% (2/19) of patients with an
EC50 of greater than 10 nmol/L required nitroglycerin treat-
ment, whereas 42% (8/19) of patients with an EC50 of less
than 10 nmol/L required nitroglycerin treatment (P = .03).
The mean saphenous vein EC50 value for exogenous ET-1
was significantly lower than the ITA value (6.5 ± 0.9 vs 10.2
± 0.9 nmol/L, P = .005).
Discussion
The bioactive peptide ET-1 has been shown to mediate vaso-
constriction of the pulmonary and systemic circulation and
influence myocardial contractility.2,10 Therefore, the overall
goal of the present study was to identify the temporal pro-
duction and concentration of ET-1 throughout the CABG
perioperative period and to identify potential associations
between ET-1 and specific postoperative parameters of
recovery. The results of the present study demonstrated that
pulmonary and systemic arterial ET-1 levels were persis-
tently elevated in the perioperative period and that ET-1 sen-
sitivity was clearly documented in conduits used for CABG.
Moreover, the results of the present study provide evidence
to suggest that higher ET-1 levels and greater ET-1 conduit
sensitivity may be associated with specific indices of post-
operative recovery.
Systemic and pulmonary arterial ET-1 levels were signif-
icantly elevated during the operation over baseline values in
patients undergoing CABG, with a secondary increase
occurring 24 hours into the postoperative period. These
results are consistent with some previously published studies
in which elevated ET-1 levels were detected during the peri-
operative period of cardiac operations.5,6 The cause for the
increased perioperative ET-1 levels observed during CABG
is probably multifactorial, including reduced ET-1 metabo-
lism during CPB from reduced pulmonary vascular flow,
damage to the endothelium during CPB caused by absent
pulsatile perfusion, increased myocardial ET-1 production
and release after reperfusion, increased stress from opera-
tions, and enhanced ET-1 biosynthesis caused by thrombox-
ane release from activated platelets during CPB.11-14
Postoperative increases in ET-1 may be related to increased
physiologic stress, as evidenced by peak levels of plasma
catecholamines and stress hormones in the immediate post-
operative period of CABG.15
Increased systemic arterial ET-1 levels in the early post-
operative period would in turn result in increased perfusion
of ET-1 within the myocardium. This would result in expo-
sure of the coronary vasculature and myocardial cells to
increased ET-1 levels, without the benefit of metabolism
and clearance by the pulmonary vasculature.13,16 Moreover,
several recent reports have shown a capacity for production
TABLE 2. Hemodynamic parameters before and after CPB
Post-CPB Postoperative
Pre-CPB 1⁄2 h 6 h 24 h
Heart rate (beats/min) 69 ± 17 90 ± 19* 95 ± 13*† 85 ± 12*†
Cardiac output(L/min) 4.8 ± 1.5 7.2 ± 1.8* 6.1 ± 1.6*† 6.3 ± 1.5*†
Mean arterial pressure (mm Hg) 69 ± 14 69 ± 15 76 ± 12*† 78 ± 11*†
Mean pulmonary pressure (mm Hg) 14 ± 6 17 ± 5* 21 ± 5*† 20 ± 5*†
PVR‡ (dyne · s–1 · cm–5) 83 ± 91 67 ± 47 88 ± 123 84 ± 37†
SVR (dyne · s–1 · cm–5) 1266 ± 1082 764 ± 279* 919 ± 365*† 922 ± 231*†
Data are presented as means ± SD (n = 105). PVR, Pulmonary vascular resistance; SVR, systemic vascular resistance.
*P < .05 versus pre-CPB.
†P < .05 versus 1⁄2 hour after CPB.
‡P = .16 PVR 1⁄2 hour versus 6 hours.
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of ET-1 by the myocardium.14,17,18 By using microdialysis,
a recent study by this laboratory has demonstrated that ET-
1 levels are compartmentalized within the myocardium and
that local myocardial interstitial levels are much higher
when compared with plasma levels.19 Thus, in the present
study, the concentrations of ET-1 within the myocardium
after CPB may be much higher than the documented plasma
levels. ET-1 receptor antagonists have been shown to pro-
mote recovery of left ventricular function after hypothermic
cardioplegic ischemia,7 and a reduction in isolated myocyte
contractile function by ET-1 after cardioplegic arrest and
rewarming has been demonstrated.20 However, in the
absence of cardioplegic arrest, ET-1 has been shown to have
a positive inotropic influence.21 The disparity in inotropic
effect by ET-1 may be related to the observation that ET-1
can reduce [Ca2+]i transients and activate Na+-H+ exchange,
resulting in changes in intracellular pH with alterations in
myofilament sensitivity to Ca2+ and promotion of ischemic
reperfusion injury.22-24 However, whether the increased ET-
1 levels that were observed in the present study directly
Figure 3. Pulmonary artery ET-1 levels at 6 hours postoperatively were higher in patients with elevated mean pul-
monary artery pressure (defined as greater than 20 mm Hg; left panel). In addition, pulmonary artery ET-1 levels at
6 hours postoperatively were higher in patients requiring more than 12 hours of ventilatory support (right panel).
Figure 2. Systemic arterial ET-1 levels at 6 hours postoperatively were higher in patients with prolonged ICU time
(defined as greater than 24 hours; left panel). Similarly, systemic ET-1 levels at 6 hours postoperatively were high-
er in patients with hospital stays of more than 5 days (right panel).
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influenced myocardial contractile function in the early post-
operative period remain to be established.
Patients with elevated pulmonary artery ET-1 levels post-
operatively displayed higher pulmonary artery pressures,
which were associated with prolonged ventilatory support in
the postoperative period. This agrees with the results of a
prior study in pediatric patients undergoing repair of con-
genital heart disease, in which a significant association was
observed between ET-1 levels after CPB and the maximum
pulmonary/systemic arterial pressure ratio postoperative-
ly.25 ET-1 has been demonstrated previously to cause sus-
tained vasoconstriction of the pulmonary vasculature.8,10.18
Elevated pulmonary artery ET-1 levels may therefore nega-
tively affect ventilation/perfusion ratios and pulmonary
artery pressures in the early postoperative period.26,27
The present study reported robust ET-1–induced vaso-
constriction of ITA and saphenous vein segments harvested
for use as CABGs. Several prior studies examining the
response of coronary conduits to ET-1 have shown potent
vasoconstriction produced by ET-1, even in intact endothe-
lium, with exaggerated responses in restrictive arteries and
in conduits with atherosclerotic changes.28,29 Furthermore,
threshold concentrations of ET-1 have been shown to specif-
ically amplify ITA and coronary artery contractions induced
by norepinephrine and serotonin.30,31 This study provides
the first evidence to suggest that ET-1–mediated vasocon-
striction of newly grafted ITA conduits may result in a pro-
longed requirement for the vasodilator nitroglycerin. Future
studies examining postoperative ischemia and hypertension
with an ET-1 antagonist would be useful to dissect out the
contribution of ET-1 in postoperative ischemia and hyper-
tension in patients undergoing CABG.
The increased ICU and hospital duration in patients with
elevated postoperative ET-1 levels was not surprising, con-
sidering the broad spectrum of pathophysiologic changes
associated with ET-1 after CABG. The present study
described increased inotropic, ventilatory, and vasodilative
requirements in certain subsets of patients with elevated ET-
1 in various vascular compartments after CABG, all of
which may contribute to prolonged patient recovery. First,
the present study does not demonstrate that ET-1 is an inde-
pendent contributory factor for the postoperative course
after CABG. Other inflammatory mediators that are typical-
ly generated during CPB may affect patient recovery, such
as leukotrienes, bradykinin, and complement, which were
not considered. Second, the sample size of the present study
was limited and therefore prevented a stasticially robust
analysis of the direct relationship between ET-1 and postop-
erative outcomes. Patients selected for these studies were
those undergoing elective CABG procedures, and therefore
confounding factors, such as comorbidities, and other pre-
operative factors were not considered in the study design.
For example, alterations in vascular sensitivity to ET-1 have
been reported in models of diabetes.32 The present study
was not designed to differentiate the relationship of changes
in ET-1 to diabetes in the postoperative period. Thus, the
increased ET-1 levels that were observed in a selected group
of patients with a more complex postoperative course may
represent ET-1 release as a compensatory response to other
underlying mechanisms. Nevertheless, the present study
demonstrated that the potent bioactive peptide ET-1 is
increased in various vascular compartments after CABG
and CPB, which in turn may contribute to a more complex
postoperative course.
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